1. Anemia remains a multifactorial condition with varied etiologies and patient responses to therapy. Conventional treatments often overlook individual biochemical and genetic variability. Exploring plant-based botanicals—like Carica papaya and other edible medicinal plants—could provide novel bioactive compounds with hematopoietic and antioxidant potential. I am considering a translational research pathway from animal models to clinical evaluation, with a focus on personalized medicine.

2. What challenges and opportunities do you foresee in designing such preclinical-to-clinical studies to ensure efficacy, safety, and individualized therapeutic outcomes?

3. Suggest a scientific road map to actualize this.